ADA: Lilly makes its case for oral GLP-1 orforglipron A first look at the phase 3 data with Eli Lilly's oral GLP-1 agonist orforglipron reveals encouraging blood sugar control data in patients with type 2 diabetes, and a side-effect profile free of the liver toxicity that scuppered rival candidates from Pfizer
She may also recommend it if you: Need a more affordable weight loss option Are looking for short-term support for your weight loss journey Can't tolerate GLP-1 medications like semaglutide due to stomach issues Don't have insurance coverage for newer weight loss medications Why choose phentermine over GLP-1 weight-loss drugs
Some hallmarks include: To try to prevent facial changes associated with rapid weight loss, consider a more gradual approach instead
Most dermatologists and researchers agree that GLP-1 hair loss is primarily triggered by the rapid weight loss these drugs produce, not by the drug itself damaging your hair follicles
These ingredients are recognized for their potential in supporting metabolism, aiding appetite management, promoting fat utilization, and supporting healthy blood sugar levels already in the normal range
